Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
{{output}}
CD3 bispecific antibodies (BsAbs) targeting delta-like ligand 3 (DLL3) have emerged as promising candidates in cancer immunotherapy by enabling T-cell-mediated tumor lysis. A critical unmet need is to establish structural correlates of their preclinical activi... ...
